Gyre Therapeutics projects $400-600M in F351 revenue within 5 years; provides Cullgen TRK degrader update

GYRE THERAPEUTICS, INC.

Company sees potential $400-600M revenue for Hydronidone (F351) in liver fibrosis within 5 years.
Expects ETUARY for lung fibrosis to sustain ~$100M absent near-term generic competition.
Sees 20-25% net margins for commercial products; favorable R&D tax deductibility in Beijing/Shanghai campuses.
Cullgen's TRK degrader CG001419 Phase 2 pain trial enrolling at doses expected to show ~95% TRK degradation.
Cullgen's degrader antibody conjugates (DAC) show ~10-100x potency vs standalone degrader in vitro/animal models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.